Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome

Pediatr Blood Cancer. 2015 Jun;62(6):1084-6. doi: 10.1002/pbc.25382. Epub 2015 Jan 13.

Abstract

Noonan syndrome (NS; MIM 163950) is an autosomal dominant syndrome which is clinically diagnosed by the distinct facial features, short stature, cardiac anomalies and developmental delay. About 50% of cases are associated with gain of function mutations in PTPN11 gene which leads to activation of the RAS/mitogen-activated protein kinase signaling pathway. This is known to have a role in tumorigenesis. Despite this, only limited reports of solid tumors (Fryssira H, Leventopoulos G, Psoni S, et al. Tumor development in three patients with Noonan syndrome. Eur J Pediatr 2008;167:1025-1031; Schuettpelz LG, McDonald S, Whitesell K et al. Pilocytic astrocytoma in a child with Noonan syndrome. Pediatr Blood Cancer 2009;53:1147-1149; Sherman CB, Ali-Nazir A, Gonzales-Gomez I, et al. Primary mixed glioneuronal tumor of the central nervous system in a patient with Noonan syndrome. J Pediatr Hematol Oncol 2009;31:61-64; Sanford RA, Bowman R, Tomita T, et al. A 16 year old male with Noonan's syndrome develops progressive scoliosis and deteriorating gait. Pediatr Neurosurg 1999;30:47-52) and no prior reports of optic gliomas have been described in patients with NS. We present here a patient with NS with a PTPN11 mutation and an optic pathway pilomyxoid astrocytoma.

Keywords: Noonan syndrome; PTPN11; optic nerve astrocytoma.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Astrocytoma / etiology*
  • Humans
  • Male
  • Mutation
  • Noonan Syndrome / complications*
  • Noonan Syndrome / genetics
  • Optic Nerve Neoplasms / etiology*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics

Substances

  • PTPN11 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 11